NewAmsterdam Pharma (NAMS) Total Current Liabilities (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Total Current Liabilities of $67.4 million for Q1 2026, down 21.41% sequentially from $85.8 million in Q4 2025, and up 64.79% YoY from $40.9 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Total Current Liabilities (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Total Current Liabilities for 6 years, with the latest figure at $67.4 million in Q1 2026.
- Quarterly Total Current Liabilities rose 64.79% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.4 million (up 64.79% YoY) and the FY2025 annual result came in at $85.8 million, down 19.76% from the prior year.
- Total Current Liabilities declined to $67.4 million in Q1 2026 per NAMS's latest filing, from $85.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $106.9 million in Q4 2024 and troughed at $41743.9 in Q2 2023.
- A 5-year average of $52.4 million and a median of $47.6 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 108435.58% in 2024, then slumped 31.5% in 2025.
- Over 5 years, Total Current Liabilities stood at $36.2 million in 2022, then jumped by 37.92% to $49.9 million in 2023, then jumped by 114.28% to $106.9 million in 2024, then dropped by 19.76% to $85.8 million in 2025, then fell by 21.41% to $67.4 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $67.4 million, $85.8 million, and $58.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 72.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.97 Mn |
| Mar 31, 2026 | 67.42 Mn |
| Dec 31, 2025 | 85.79 Mn |
| Sep 30, 2025 | 58.27 Mn |
| Jun 30, 2025 | 36.51 Mn |
| Mar 31, 2025 | 40.91 Mn |
| Dec 31, 2024 | 106.92 Mn |
| Sep 30, 2024 | 41.26 Mn |
| Jun 30, 2024 | 45.31 Mn |
| Mar 31, 2024 | 59.73 Mn |
| Dec 31, 2023 | 49.90 Mn |
| Jun 30, 2023 | 41,743.92 |
| Dec 31, 2022 | 36.18 Mn |
| Dec 31, 2021 | 11.30 Mn |